- AVNR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $185.0 million.
- AVNR is down 6% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AVNR with the Ticky from Trade-Ideas. See the FREE profile for AVNR NOW at Trade-Ideas More details on AVNR: Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Currently there are 3 analysts that rate AVANIR Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for AVANIR Pharmaceuticals has been 4.2 million shares per day over the past 30 days. AVANIR has a market cap of $2.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.78 and a short float of 11.7% with 0.93 days to cover. Shares are up 228.6% year-to-date as of the close of trading on Friday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.